Top Markets
Coin of the day
Catalent, Inc. Catalent, Inc.

Catalent, Inc.

CTLT
Rank in Stocks #1926
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Share Price
$63.48
Last synced: 2024-12-17
Market Cap
$11.52B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Catalent, Inc. (CTLT)

Category

Revenue for Catalent, Inc. (CTLT)
Revenue in Sep 2024 TTM: $4.42B
According to Catalent, Inc. latest financial reports the company's current revenue (TTM) is $4.42B. In 2023 the company made a revenue of $4.28B a decrease compared to the revenue in the year 2022 that was $4.83B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Catalent, Inc. from 2011 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $4.42B 0.94%
2024 $4.38B 2.46%
2023 $4.28B -11.43%
2022 $4.83B 20.76%
2021 $4.00B 29.21%
2020 $3.09B 22.89%
2019 $2.52B 2.22%
2018 $2.46B 18.70%
2017 $2.08B 12.30%
2016 $1.85B 0.94%
2015 $1.83B 0.17%
2014 $1.83B 1.52%
2013 $1.80B 6.22%
2012 $1.69B 10.64%
2011 $1.53B 0.00%
Revenue for similar companies or competitors